Moderna, Inc.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the Uni…
Biotechnology
US, Cambridge [HQ]
MRNA/Financial Reporting
Income Statements
8 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 101.00 | 176.00 | 122.00 | 48.00 | 274.00 | 17,736.00 | 19,263.00 | 6,754.00 | |
|
EPS
|
-0.58 | -0.68 | -4.74 | -1.55 | -1.96 | 30.28 | 21.22 | -12.34 | |
| Diluted in mil. | -0.58 | -0.68 | -4.74 | -1.55 | -1.96 | 28.31 | 20.10 | -12.34 | |
|
Profit
|
101.00 | 176.00 | -331.00 | 17.00 | 266.00 | 15,119.00 | 13,847.00 | 2,061.00 | |
| Gross Margin | 100.00 | 100.00 | -270.64 | 35.42 | 97.11 | 85.24 | 71.88 | 30.52 | |
| Pre Tax | -215.00 | -255.00 | -384.00 | -514.00 | -744.00 | 13,285.00 | 9,575.00 | -3,942.00 | |
| Profit Margin | -211.91 | -144.65 | -313.77 | -1,071.52 | -271.24 | 74.90 | 49.71 | -58.37 | |
| ETR | -0.48 | 0.03 | -0.08 | 0.14 | -0.34 | 8.15 | 12.67 | -19.58 | |
| Net | -216.00 | -255.00 | -384.00 | -514.00 | -747.00 | 12,202.00 | 8,362.00 | -4,714.00 | |
| Profit Margin | -212.94 | -144.61 | -314.04 | -1,070.07 | -272.16 | 68.80 | 43.41 | -69.80 | |
| EBITDA | -208.00 | -248.00 | -413.00 | -545.00 | -763.00 | 13,296.00 | 9,768.00 | -3,211.00 | |
| EBITDA Margin | -205.50 | -140.60 | -337.33 | -1,136.06 | -278.02 | 74.97 | 50.71 | -47.54 | |
| Operating Income | -223.00 | -269.00 | -413.00 | -545.00 | -763.00 | 13,296.00 | 9,420.00 | -4,239.00 | |
| Operating Margin | -220.39 | -152.20 | -337.33 | -1,136.06 | -278.02 | 74.97 | 48.90 | -62.76 | |
| Interest Income | 11.00 | 15.00 | 27.00 | 38.00 | 24.00 | 18.00 | 200.00 | 421.00 | |
| Loss | -325.00 | -446.00 | -535.00 | -593.00 | -1,037.00 | -4,440.00 | -9,843.00 | -10,993.00 | |
| Cost of Revenue | - - | - - | -454.00 | -31.00 | -7.00 | -2,617.00 | -5,416.00 | -4,693.00 | |
|
Operating Expenses
|
-325.00 | -446.00 | -535.00 | -593.00 | -1,029.00 | -1,823.00 | -4,427.00 | -6,300.00 | |
| R&D | -274.00 | -410.00 | -454.00 | -496.00 | -1,370.00 | -1,991.00 | -3,295.00 | -4,845.00 | |
| G&A | -57.00 | -64.00 | -94.00 | -109.00 | - - | - - | -1,011.00 | -1,345.00 | |
| SG&A | -57.00 | -64.00 | -94.00 | -109.00 | -188.00 | -567.00 | -1,132.00 | -1,549.00 | |
| S&M | - - | - - | - - | - - | - - | - - | -121.00 | -204.00 | |
| Depreciation and Amortization | -15.00 | -20.00 | -24.00 | -31.00 | -31.00 | -232.00 | -348.00 | -621.00 | |
| Interest Expenses | - - | - - | - - | -6.00 | -9.00 | -18.00 | -29.00 | -38.00 | |
| Other Expenses | -2.00 | -1.00 | -1.00 | -31.00 | -18.00 | -11.00 | -155.00 | -86.00 | |
|
WA Shares Outstanding
|
376.00 | 376.00 | 81.00 | 330.00 | 381.00 | 403.00 | 394.00 | 382.00 | |
| Diluted | 376.00 | 376.00 | 81.00 | 330.00 | 381.00 | 431.00 | 416.00 | 382.00 |